Paper36928165
RNA therapeutics.
Hastings ML and 1 other. RNA, 2023. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. RNA therapeutics. Papers, record 36928165. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36928165
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| RNA | Major topic |
| Drug Delivery Systems | Major topic |
| RNA, Small Interfering |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 DC012596 | NIDCD NIH HHS | United States | R01DC012596 | PubMed and NIH | NIH RePORTER |
| R37 GM042699 | NIGMS NIH HHS | United States | R01GM042699 | PubMed and NIH | NIH RePORTER |
| F31 NS076237 | NINDS NIH HHS | United States | F31NS076237 | PubMed and NIH | NIH RePORTER |
| P01 CA013106 | NCI NIH HHS | United States | P01CA013106 | PubMed and NIH | NIH RePORTER |
| R01 GM042699 | NIGMS NIH HHS | United States | R01GM042699 | PubMed and NIH | NIH RePORTER |
| R01 NS069759 | NINDS NIH HHS | United States | R01NS069759 | PubMed and NIH | NIH RePORTER |
| R37GM042699 | NIH | NIH RePORTER |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41221298 | The role and targeting strategies of non-coding RNAs in immunotherapy resistance in oral squamous cell carcinoma. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41221298 | PubMed |
| 40921731 | Developing Potent Therapeutics for Liver Cancer Chemoresistance via an RNA Nanotech and Series-Circuit-Christmas-Bulb Mechanism Targeting ABC Transporters. | Mol Pharm | 2026 | https://conductscience.org/library/papers/40921731 | PubMed |
| 40884791 | The bidirectional interplay between RNA processing and mechanotransduction. | Cell Rep | 2025 | https://conductscience.org/library/papers/40884791 | PubMed |
| 40515593 | RNA-targeting therapeutics: drugging the undruggable. | Future Med Chem | 2025 | https://conductscience.org/library/papers/40515593 | PubMed |
| 40197199 | The Regulatory Effects of Electroacupuncture on the Intestinal Flora of Mice with Ulcerative Colitis. | Comb Chem High Throughput Screen | 2026 | https://conductscience.org/library/papers/40197199 | PubMed |
| 40182424 | Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/40182424 | PubMed |
| 40014258 | Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design. | Ther Innov Regul Sci | 2025 | https://conductscience.org/library/papers/40014258 | PubMed |
| 39967972 | Co-host ncRNA MIR503HG/miR-503-5p antagonistically interfere with the crosstalk between fibroblasts and microvascular endothelial cells by affecting the production of LMW FGF2 in pterygium. | Int J Ophthalmol | 2025 | https://conductscience.org/library/papers/39967972 | PubMed |
| 39699235 | Essential Considerations for Free Energy Calculations of RNA-Small Molecule Complexes: Lessons from the Theophylline-Binding RNA Aptamer. | J Chem Inf Model | 2025 | https://conductscience.org/library/papers/39699235 | PubMed |
| 39598489 | The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39598489 | PubMed |
| 39011892 | Single-mode termination of phage transcriptions, disclosing bacterial adaptation for facilitated reinitiations. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/39011892 | PubMed |
| 39005062 | Biogenesis and Function of circRNAs in Pulmonary Fibrosis. | Curr Gene Ther | 2024 | https://conductscience.org/library/papers/39005062 | PubMed |
| 38977892 | A (metaphorical) moment for RNA-based biotechnology? : Current metaphors for RNA limit development of and public communication about RNA-based technologies. | EMBO Rep | 2024 | https://conductscience.org/library/papers/38977892 | PubMed |
| 38919398 | DNA-based nanostructures for RNA delivery. | Med Rev (2021) | 2024 | https://conductscience.org/library/papers/38919398 | PubMed |
| 38351661 | Are non-protein coding RNAs junk or treasure?: An attempt to explain and reconcile opposing viewpoints of whether the human genome is mostly transcribed into non-functional or functional RNAs. | Bioessays | 2024 | https://conductscience.org/library/papers/38351661 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36928165
GET https://conductscience.org/api/papers/v1/36928165/authors